Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88956 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL57753 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL16861355 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL16861356 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL29511344 | 0.99 | DPP4 (0.40) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL14567882 | 0.88 | DPP4 (0.42) | DPP4GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL12203122 | 0.86 | DPP4 (0.35) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL90441 | 0.86 | DPP4 (0.35) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL16169554 | 0.86 | TUBB1 (0.34) | TUBB1GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL14210216 | 0.86 | TUBB1 (0.34) | TUBB1GLO1CYP2C9CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | Sumitomo Pharma Co., Ltd. (JP) | 2025-05-27 | — | — | US | disclosed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-12178879-B2 | Hemiasterlin derivative and antibody-drug conjugate thereof | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-31 | — | — | US | disclosed |
| EP-3666787-B9 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| EP-4321523-A2 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | TUBA1C, TUBB1, TUBB | DPP4 4652/4885TUBB1 2/4885GLO1 1802/4885 |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | SHBG, CYP11A1, CYP11B1 | DPP4 4255/4885TUBB1 1472/4885GLO1 988/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | DPP4 2083/4885TUBB1 624/4885GLO1 3986/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | DPP4 2059/4885TUBB1 506/4885GLO1 1638/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | DPP4 4796/4885TUBB1 1668/4885GLO1 2564/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | DPP4 2986/4885TUBB1 106/4885GLO1 4394/4885 |
| US-12178879-B2 | Hemiasterlin derivative and antibody-drug conjugate thereof | SHBG, HSD17B7, CYP17A1 | DPP4 3265/4885TUBB1 802/4885GLO1 2136/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | DPP4 2986/4885TUBB1 106/4885GLO1 4394/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | DPP4 2083/4885TUBB1 624/4885GLO1 3986/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | DPP4 4827/4885TUBB1 1157/4885GLO1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.